Since the advent of tamoxifen, a selective estrogen receptor modulator, in the 1970s, endocrine therapy agents with different mechanisms, including aromatase inhibitors and selective estrogen receptor degraders, have been developed and have become the mainstay treatment options for HR-positive breast cancer in both adjuvant and metastatic settings [5]. The gene discussed is ESR1; the disease is breast cancer.